Main Article Content
Diabetes mellitus (DM) is a metabolic disease with a large incidence in the world and constitutes a global health problem. By 2030 it is estimated that there will be around 439 million people suffering from DM. Diabetes mellitus is a metabolic disease caused by a lack or absence of the hormone insulin. In type 2 DM pharmacotherapy can be given one of which is insulin. To monitor therapy, random blood glucose, glycated hemoglobin (HbA1c) and glycated albumin (GA) levels can be examined. The objective of this study was to determine the relationship of glycated albumin and glycated hemoglobin (HbA1c) with random blood glucose in insulin-treated diabetics.
A cross-sectional study was conducted involving 92 type 2 diabetic patients treated with insulin. The study used a questionnaire and blood samples. We measured the GA , HbA1C and random blood glucose levels. A multiple linear regression was used to analyze the data.
Mean HbA1c was 9.21 ± 2.15%, mean glycated albumin was 24.4 ± 8.65%, and mean blood glucose was 229.47 ± 98.7 mg/dL. Multiple linear regression tests showed that HbA1c (B= 5,544; â=0.121; p=0.420) and GA (B=5.899; â=0.517; p=0.001) was signigicantly corelated with random blood gucose, respectively, indicating that glycated albumin is significantly related to and has the greatest influence on glucose level.
Glycated albumin is correlated with and has greater influence on glucose level than does HbA1c. Glycated albumin could be a better marker for glycemic control than glycated hemoglobin in diabetic patients treated with insulin.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
Chamnan P, Simmons RK, Forouhi NG, et al. Incidence of type 2 diabetes mellitus using proposed HbA1c diagnostic criteria in the European Prospective Investigation of Cancer-Norfolk Cohort. Diabetes Care 2011;34:950-6. DOI: 10.2337/dc09-2326.
Freitas PAC, Ehlert LR, Camargo JL. Glycated albumin: a potential biomarker in diabetes. Arch Endocrinol Metab 2017;61: 296-304. DOI: 10.1590/2359-3997000000272.
American Diabetes Association: Standard of medical care in diabetes-2016. Diabetes Care 2016;39 Suppl 1:S1-S112. DOI: 10.2337/ dc14-S081.
Baynest HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab 2015;6:1-9. DOI: 10.4172/2155-6156.1000541.
International Diabetes Federation. Diabetes risk factors. Brussels: International Diabetes Federation;2019.
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2015;38 Suppl 1:S8–16 DOI: 10.2337/dc15-S005.
Gul A, Sharif N, Zahoorullah, et al. Diabetes: comparison of HbA1c and serum glycated albumin levels as monitoring tool. Prof Med J 2018;25:109-14. DOI: 10.29309/TPMJ/18. 4263.
Indranila KS. Glycated hemoglobin A1c as a biomarker predictor for diabetes mellitus, cardiovascular disease and inflammation. Indones J Clin Pathol Med Lab 2017;23:191-6. DOI: http://dx.doi.org/10.24293/ijcpml.v23i2.1145.
Ake A, Saraswati MR, Widiana IGR. Glycated albumin sebagai penanda kontrol glikemik pada penderita diabetes melitus tipe 2. Udayana J Int Med 2017;1:1-7. DOI: https://doi.org/10.36216/jpd.v1i1.10.
Mahajan RD, Mishra B. Using glycated hemoglobin HbA1c for diagnosis of diabetes mellitus: an Indian perspective. Int J Biol Med Res 2011;2:508-12.
Welsh KJ, Kirkman MS, Sacks DB. Role of glycated proteins in the diagnosis and management of diabetes: research gaps and future directions. Diabetes Care 2016;39:1299-306. DOI:10.2337/dc15-2727.
Koga M, Kasayama M. Clinical impact of glycated albumin as another glycemic control marker. Endocrine J 2010;57:751-62.
Hamaguchi T, Koga M, Murai J, et al. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks. J Diabetes Investig 2012;3:175-8. DOI: 10.1111/j.2040-11242011.00167x.2012.
Kohzuma T, Koga M. Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus. Mol Diagn Ther 2010;14: 49-51. DOI:10.2165/11317390-000000000-00000.
Yoon HJ, Lee YH, Kim KJ, et al. Glycated albumin levels in patients with type 2 diabetes increase relative to HbA1c with time. Biomed Res Int 2015;2015:576306. DOI: 10.1155/ 2015/576306.
Paroni R, Ceriotti F, Galanello R, et al. Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 2007;40:1398-405. DOI: 10.1016/j. clinbiochem.2007.08.001.
Bio Rad. D-10 Hemoglobin testing system for hemoglobin A1c. Bio-Rad Laboratories, Inc.; 2019.
Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. J Diabetes Invest 2014;5:507-12. DOI: 10.1111/jdi.12177.
Kementerian Kesehatan RI InfoDatin Pusat Data and Informasi. Situasi and analisis diabetes. Jakarta : Kementerian Kesehatan RI InfoDatin Pusat Data and Informasi;2014.
Simanjuntak S, Darmanta B, Kartikasari EY, et al. Hubungan glycated albumin dengan HbA1c pada pasien diabetes mellitus tipe II. Jurnal Kedokteran Methodist 2017;9:631-8.
Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011;93:645-58. DOI: 10.1016/j. biochi.2010.12.003.
Koga M, Murai J, Saito H, et al. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care 2010;33:270-2. DOI: 10.2337/ dc09-1002.
Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J 2012;36: 98-107. DOI: 10.4093/dmj.2012.36.2.98.
Ueda Y, Matsumoto H. Recent topics in chemical and clinical research on glycated albumin. J Diabetes Sci Technol 2015;9:177-82. DOI: 10.1177/1932296814567225.
Whaley-Connell A, Sowers JR. Implications for glucose measures in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complication Study. Diabetes 2014;63:45-7. DOI: 10.2337/ db13-1497.
Won HK, Kim KJ, Lee BW, et al. Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments. Diabet Med 2012;29:74-9. DOI: 10.1111/j.1464-5491. 2011.03386.x.
Lee EY, Lee BW, Kim D, et al. Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetol 2011;48: 167-72. DOI: 10.1007/s00592-010-0242-0.